Ying Zhou1,2,3, Yanrong Jiang4,5,6, Yujing Bai1,2,3, Jing Wen1,2,3, Li Chen1,2,3. 1. Department of Ophthalmology, Peking University People's Hospital, 11 Xizhimen South Street, Xicheng District, 100044, Beijing, China. 2. Key Laboratory of Vision Loss and Restoration, Peking University, Ministry of Education, Beijing, China. 3. Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Beijing, China. 4. Department of Ophthalmology, Peking University People's Hospital, 11 Xizhimen South Street, Xicheng District, 100044, Beijing, China. drjiangyr@gmail.com. 5. Key Laboratory of Vision Loss and Restoration, Peking University, Ministry of Education, Beijing, China. drjiangyr@gmail.com. 6. Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Beijing, China. drjiangyr@gmail.com.
Abstract
PURPOSE: To evaluate vascular endothelial growth factor (VEGF) plasma levels before and after intravitreal injection of ranibizumab in patients with retinopathy of prematurity (ROP). METHODS: Case series study. Eleven infants with type 1 pre-threshold ROP were treated with intravitreal ranibizumab 0.5 mg. Blood samples were collected before intravitreal injection of ranibizumab and 1 day, 1 week, 2 weeks, and 4 weeks after injection. Concentration of plasma VEGF was measured by enzyme-linked immunosorbent assays (ELISA). RESULTS: The mean ± standard deviation of plasma VEGF concentration of the available samples before and 1 day, 1 week, 2 weeks, and 4 weeks after a total of 0.5 mg ranibizumab injection were 46.07 ± 9.40 pg/ml (n = 11), 10.59 ± 7.32 pg/ml (n = 5), 45.76 ± 6.75 pg/ml (n = 5), 62.44 ± 15.51 pg/ml (n = 5), and 56.82 ± 12.78 pg/ml (n = 4) respectively. A significant reduction was found in the plasma VEGF levels 1 day after intravitreal injection of ranibizumab (P = 0.002). No significant differences were found between before and 1 week, 2 weeks, and 4 weeks after the injection. CONCLUSIONS: Intravitreal ranibizumab reduced plasma VEGF levels 1 day after injection in infants with ROP. This effect disappeared 1 week after the injection. Intravitreal ranibizumab did not induce prolonged systemic VEGF suppression.
PURPOSE: To evaluate vascular endothelial growth factor (VEGF) plasma levels before and after intravitreal injection of ranibizumab in patients with retinopathy of prematurity (ROP). METHODS: Case series study. Eleven infants with type 1 pre-threshold ROP were treated with intravitreal ranibizumab 0.5 mg. Blood samples were collected before intravitreal injection of ranibizumab and 1 day, 1 week, 2 weeks, and 4 weeks after injection. Concentration of plasma VEGF was measured by enzyme-linked immunosorbent assays (ELISA). RESULTS: The mean ± standard deviation of plasma VEGF concentration of the available samples before and 1 day, 1 week, 2 weeks, and 4 weeks after a total of 0.5 mg ranibizumab injection were 46.07 ± 9.40 pg/ml (n = 11), 10.59 ± 7.32 pg/ml (n = 5), 45.76 ± 6.75 pg/ml (n = 5), 62.44 ± 15.51 pg/ml (n = 5), and 56.82 ± 12.78 pg/ml (n = 4) respectively. A significant reduction was found in the plasma VEGF levels 1 day after intravitreal injection of ranibizumab (P = 0.002). No significant differences were found between before and 1 week, 2 weeks, and 4 weeks after the injection. CONCLUSIONS: Intravitreal ranibizumab reduced plasma VEGF levels 1 day after injection in infants with ROP. This effect disappeared 1 week after the injection. Intravitreal ranibizumab did not induce prolonged systemic VEGF suppression.
Entities:
Keywords:
Anti-VEGF therapy; Plasma VEGF; Ranibizumab; Retinopathy of prematurity
Authors: William V Good; Robert J Hardy; Velma Dobson; Earl A Palmer; Dale L Phelps; Betty Tung; Maryann Redford Journal: Arch Ophthalmol Date: 2010-04-12
Authors: Sophie J Bakri; Melissa R Snyder; Joel M Reid; Jose S Pulido; Mohamed K Ezzat; Ravinder J Singh Journal: Ophthalmology Date: 2007-12 Impact factor: 12.079
Authors: Robert L Avery; Alessandro A Castellarin; Nathan C Steinle; Dilsher S Dhoot; Dante Joseph Pieramici; Robert See; Stephen Couvillion; Ma'an A Nasir; Melvin D Rabena; Kha Le; Mauricio Maia; Jennifer E Visich Journal: Br J Ophthalmol Date: 2014-07-07 Impact factor: 4.638
Authors: Usha Chakravarthy; Simon P Harding; Chris A Rogers; Susan M Downes; Andrew J Lotery; Sarah Wordsworth; Barnaby C Reeves Journal: Ophthalmology Date: 2012-05-11 Impact factor: 12.079
Authors: David K Wallace; Trevano W Dean; Mary Elizabeth Hartnett; Lingkun Kong; Lois E Smith; G Baker Hubbard; Mary Lou McGregor; Catherine O Jordan; Iason S Mantagos; Edward F Bell; Raymond T Kraker Journal: Ophthalmology Date: 2018-06-07 Impact factor: 12.079
Authors: Tariq Aldebasi; Muataz A Guma; Rabia Bashir; Saif Al Saif; Waleed A Altwaijri; Abdulkareem M Al Bekairy Journal: Med Princ Pract Date: 2019-04-16 Impact factor: 1.927
Authors: Lauren A Dalvin; Mary Elizabeth Hartnett; Colin A Bretz; Cheryl R Hann; Ricky Z Cui; Alan D Marmorstein; David Sheikh-Hamad; Michael P Fautsch; Gavin W Roddy Journal: Curr Eye Res Date: 2019-08-28 Impact factor: 2.424